Functional neuroimaging in Parkinson's disease

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 5, 2012, Pages

  Niethammer, Martin ^a   Feigin, Andrew ^a   Eidelberg, David ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; LEVODOPA; RACLOPRIDE C 11; TROFOLASTAT TC 99M; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ANTIPARKINSON AGENT; DIAGNOSTIC AGENT; DOPAMINE; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BRAIN DEPTH STIMULATION; CLINICAL PRACTICE; COGNITION; DOPAMINERGIC ACTIVITY; DYSKINESIA; FUNCTIONAL NEUROIMAGING; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PROTEIN AGGREGATION; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; COGNITIVE DEFECT; DISEASE COURSE; LEWY BODY; METABOLIC ENCEPHALOPATHY; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOMOTOR DISORDER; REVIEW;

PARKINSONIA;

ANTIPARKINSON AGENTS; BRAIN DISEASES, METABOLIC; COGNITION DISORDERS; DISEASE PROGRESSION; DOPAMINE; DYSKINESIA, DRUG-INDUCED; FLUORODEOXYGLUCOSE F18; FUNCTIONAL NEUROIMAGING; HUMANS; LEVODOPA; LEWY BODIES; MAGNETIC RESONANCE IMAGING; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PSYCHOMOTOR DISORDERS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84878961999     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a009274     Document Type: Article

References (203)

1. Aarsland D, Kurz MW. 2010. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 289: 18-22.
2. Aarsland D, Zaccai J, Brayne C. 2005. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 20: 1255-1263.
3. Achard S, Salvador R, Whitcher B, Suckling J, Bullmore E. 2006. A resilient, low-frequency, small-world human brain functional network with highly connected association cortical hubs. J Neurosci 26: 63-72.
4. Adams JR, van Netten H, Schulzer M, Mak E, McKenzie J, Strongosky A, SossiV, Ruth TJ, Lee CS, Farrer M, et al. 2005. PET in LRRK2 mutations: Comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 128: 2777-2785.
5. Agdeppa ED, Kepe V, Liu J, Small GW, Huang SC, Petric A, Satyamurthy N, Barrio JR. 2003. 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): Novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol 5: 404-417.
6. Ahlskog JE, Muenter MD. 2001. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16: 448-458.
7. Albin RL, Koeppe RA, Chervin RD, Consens FB, Wernette K, Frey KA, Aldrich MS. 2000. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 55: 1410-1412.
8. Antonini A, Moeller JR, Nakamura T, Spetsieris P, Dhawan V, Eidelberg D. 1998. The metabolic anatomy of tremor in Parkinson's disease. Neurology 51: 803-810.
9. Arendt T, Bigl V, Arendt A, Tennstedt A. 1983. Loss of neurons in the nucleus basalis of Meynert in Alzheimer's disease, paralysis agitans and Korsakoff's disease. Acta Neuropathol 61: 101-108.
10. Argyelan M, Carbon M, Ghilardi MF, Feigin A, Mattis P, Tang C, Dhawan V, Eidelberg D. 2008. Dopaminergic suppression of brain deactivation responses during sequence learning. J Neurosci 28: 10687-10695.
11. Asahina M, Shinotoh H, Hirayama K, Suhara T, Shishido F, Inoue O, Tateno Y. 1995. Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Acta Neurol Scand 91: 437-443.
12. Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T. 1998. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: A positron emission tomographic study. J Neurol Neurosurg Psychiatry 65: 155-163.
13. Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, Kaplitt MG, FeiginA, Eidelberg D. 2006. Network modulation in the treatment of Parkinson's disease. Brain 129: 2667-2678.
14. Aubert I, Araujo DM, Cecyre D, Robitaille Y, Gauthier S, Quirion R. 1992. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases. J Neurochem 58: 529-541.
15. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, Irizarry MC, Klunk WE, Mathis CA, Dekosky ST, et al. 2007. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: A case report. Arch Neurol 64: 431-434.
16. Baudrexel S, Witte T, Seifried C, von Wegner F, Beissner F, Klein JC, SteinmetzH, Deichmann R, Roeper J, Hilker R. 2011. Resting state fMRI reveals increased subthalamic nucleus-motor cortex connectivity in Parkinson's disease. Neuroimage 55: 1728-1738.
17. Beck T, Vogg P, Krieglstein J. 1988. Uncoupling of cerebral blood flow and glucose utilization by dihydroergocristine in the conscious rat. N-S Arch Pharmacol 338: 82-87.
18. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. 2000. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 15: 692-698.
19. Benamer HT, Oertel WH, Patterson J, Hadley DM, Pogarell O, Hoffken H, Gerstner A, Grosset DG. 2003. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: Part 1. Baseline and 3-month observations. Mov Disord 18: 977-984.
20. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST. 2003. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study. Arch Neurol 60: 1745-1748.
21. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, Mathis Ch A, Davis JG, Moore RY, Dekosky ST. 2006. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 253: 242-247.
22. Bohnen NI, Muller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, AlbinRL. 2009. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 73: 1670-1676.
23. Borghammer P, Chakravarty M, Jonsdottir KY, Sato N, Matsuda H, Ito K, Arahata Y, Kato T, Gjedde A. 2010. Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive: Probably even at early disease stages. Brain Struct Funct 214: 303-317.
24. Bronte-Stewart H, Barberini C, Koop MM, Hill BC, Henderson JM, Wingeier B. 2009. The STN β-band profile in Parkinson's disease is stationary and shows prolonged attenuation after deep brain stimulation. Exp Neurol 215: 20-28.
25. Brooks DJ. 2005. Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx 2: 226-236.
26. Brooks DJ. 2009. Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord 24(Suppl 2): S742-S747.
27. Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, Bannister R, Marsden CD, Frackowiak RS. 1990. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 28: 547-555.
28. Brown P, Oliviero A, Mazzone P, Insola A, Tonali P, Di Lazzaro V. 2001. Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease. J Neurosci 21: 1033-1038.
29. Bruck A, Portin R, Lindell A, Laihinen A, Bergman J, Haaparanta M, Solin O, Rinne JO. 2001. Positron emission tomography shows that impaired frontal lobe functioning in Parkinson's disease is related to dopaminergic hypofunction in the caudate nucleus. Neurosci Lett 311: 81-84.
30. Bruck A, Aalto S, Nurmi E, Bergman J, Rinne JO. 2005. Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease. Neurobiol Aging 26: 891-898.
31. Burack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. 2010. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 74: 77-84.
32. Calhoun VD, Maciejewski PK, Pearlson GD, Kiehl KA. 2008. Temporal lobe and "default" hemodynamic brain modes discriminate between schizophrenia and bipolar disorder. Hum Brain Mapp 29: 1265-1275.
33. Calon F, Dridi M, Hornykiewicz O, Bedard PJ, Rajput AH, Di Paolo T. 2004. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127: 1075-1084.
34. Carbon M, Ghilardi MF, Feigin A, Fukuda M, Silvestri G, Mentis MJ, Ghez C, Moeller JR, Eidelberg D. 2003. Learning networks in health and Parkinson's disease: Reproducibility and treatment effects. Hum Brain Mapp 19: 197-211.
35. Carbon M, Ma Y, Barnes A, Dhawan V, Chaly T, Ghilardi MF, Eidelberg D. 2004. Caudate nucleus: Influence of dopaminergic input on sequence learning and brain activation in Parkinsonism. Neuroimage 21: 1497-1507.
36. Carlsson T, Carta M, Munoz A, Mattsson B, Winkler C, Kirik D, Bjorklund A. 2009. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 132: 319-335.
37. Carta M, Carlsson T, Kirik D, Bjorklund A. 2007. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130: 1819-1833.
38. Cenci MA, Lindgren HS. 2007. Advances in understanding L-DOPA-induced dyskinesia. Curr Opin Neurobiol 17: 665-671.
39. Cenci MA, Lundblad M. 2006. Post-versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 99: 381-392.
40. Colloby SJ, Pakrasi S, Firbank MJ, Perry EK, Piggott MA, Owens J, Wyper DJ, McKeith IG, Burn DJ, Williams ED, et al. 2006. In vivo SPECT imaging of muscarinic acetylcholine receptors using (R, R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. Neuroimage 33: 423-429.
41. Constantinescu R, Richard I, Kurlan R. 2007. Levodopa responsiveness in disorders with parkinsonism: A review of the literature. Mov Disord 29: 29.
42. Cools R. 2006. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 30: 1-23.
43. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. 2002. Dopaminergic modulation of high-level cognition in Parkinson's disease: The role of the prefrontal cortex revealed by PET. Brain 125: 584-594.
44. Damoiseaux JS, Rombouts SA, Barkhof F, Scheltens P, Stam CJ, Smith SM, Beckmann CF. 2006. Consistent resting-state networks across healthy subjects. Proc Natl Acad Sci 103: 13848-13853.
45. de la Fuente-Fernandez R, Sossi V, Huang Z, Furtado S, Lu JQ, Calne DB, RuthTJ, Stoessl AJ. 2004. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: Implications for dyskinesias. Brain 127: 2747-2754.
46. DeLong MR, Wichmann T. 2007. Circuits and circuit disorders of the basal ganglia. Arch Neurol 64: 20-24.
47. Dentresangle C, Veyre L, Le Bars D, Pierre C, Lavenne F, Pollak P, Guerin J, Froment JC, Brousolle E. 1999. Striatal D2 dopamine receptor status in Parkinson's disease: An [18F]dopa and [11C]raclopride PET study. Mov Disord 14: 1025-1030.
48. Dhawan V, Eidelberg D. 2006. PET imaging in Parkinson's disease and other neurodegenerative disorders. In Neurobiology of disease (ed. Gilman S), pp. 821-828. Academic Press, San Diego.
49. Eckert T, Tang C, Eidelberg D. 2007a. Assessment of the progression of Parkinson's disease: A metabolic network approach. Lancet Neurol 6: 926-932.
50. Eckert T, Van Laere K, Tang C, Lewis DE, Edwards C, Santens P, Eidelberg D. 2007b. Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 34: 496-501.
51. Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, Feigin A, Eidelberg D. 2008. Abnormal metabolic networks in atypical parkinsonism. Mov Disord 23: 727-733.
52. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O'Keefe G, Nagren K, Chaudhury KR, et al. 2008. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 79: 1331-1338.
53. Edvinsson L, Krause D. 2002. Catecholamines. In Cerebral blood flow and metabolism (ed. Edvinsson L, Krause D), pp. 191-211. Lippincott Williams & Wilkins, Philadelphia.
54. Eidelberg D. 2009. Metabolic brain networks in neurodegenerative disorders: A functional imaging approach. Trends Neurosci 32: 548-557.
55. Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, CedarbaumJ, Greene P, Fahn S, Rottenberg DA. 1990. The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Mov Disord 5: 203-213.
56. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, ChalyT, Robeson W, Margouleff D, Przedborski S, et al. 1994. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14: 783-801.
57. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, BelakhlefA, Mandel F, Przedborski S, Fahn S. 1995a. Early differential diagnosis of Parkinson's disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 45: 1995-2004.
58. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, RobesonW, Dahl JR, Margouleff D. 1995b. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. J Nucl Med 36: 378-383.
59. Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. 2000. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 123 (Pt 6): 1155-1160.
60. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, et al. 2004. Rivastigmine for dementia associated with Parkinson's disease. New Engl J Med 351: 2509-2518.
61. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. 2007. Levodopa-induced dyskinesias. Mov Disord 22: 1379-1389.
62. Feigin A, Fukuda M, Dhawan V, Przedborski S, Jackson-Lewis V, Mentis MJ, Moeller JR, Eidelberg D. 2001. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 57: 2083-2088.
63. Feigin A, Antonini A, Fukuda M, De Notaris R, Benti R, Pezzoli G, Mentis MJ, Moeller JR, Eidelberg D. 2002. Tc-99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism. Mov Disord 17: 1265-1270.
64. Feigin A, Ghilardi MF, Carbon M, Edwards C, Fukuda M, Dhawan V, MargouleffC, Ghez C, Eidelberg D. 2003. Effects of levodopa on motor sequence learning in Parkinson's disease. Neurology 60: 1744-1749.
65. Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, Paulsen JS, DhawanV, Eidelberg D. 2007. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 130: 2858-2867.
66. Filippi L, Manni C, Pierantozzi M, Brusa L, Danieli R, Stanzione P, Schillaci O. 2005. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms. Nucl Med Commun 26: 421-426.
67. Fodero-Tavoletti MT, Smith DP, McLean CA, Adlard PA, Barnham KJ, Foster LE, Leone L, Perez K, Cortes M, Culvenor JG, et al. 2007. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 27: 10365-10371.
68. Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL. 2009. In vitro characterisation of BF227 binding to α-synuclein/Lewy bodies. Eur J Pharmacol 617: 54-58.
69. Fox MD, Raichle ME. 2007. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 8: 700-711.
70. Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. 2001. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the α(2) adrenoceptor antagonist idazoxan. Mov Disord 16: 642-650.
71. Fox SH, Lang AE, Brotchie JM. 2006. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure. Mov Disord 21: 1578-1594.
72. Fujita M, Ichise M, Zoghbi SS, Liow JS, Ghose S, Vines DC, Sangare J, Lu JQ, Cropley VL, Iida H, et al. 2006. Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Ann Neurol 59: 174-177.
73. Fukuda M, Mentis M, Ghilardi MF, Dhawan V, Antonini A, Hammerstad J, Lozano AM, Lang A, Lyons K, Koller W, et al. 2001a. Functional correlates of pallidal stimulation for Parkinson's disease. Ann Neurol 49: 155-164.
74. Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, Lozano AM, Hammerstad J, Lyons K, Koller WC, et al. 2001b. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: A PET study of resting-state glucose metabolism. Brain 124: 1601-1609.
75. Fukuda M, Ghilardi MF, Carbon M, Dhawan V, Ma Y, Feigin A, Mentis MJ, GhezC, Eidelberg D. 2002. Pallidal stimulation for parkinsonism: Improved brain activation during sequence learning. Ann Neurol 52: 144-152.
76. Gai WP, Halliday GM, Blumbergs PC, Geffen LB, Blessing WW. 1991. Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. Brain 114 (Pt 5): 2253-2267.
77. Galvin JE, Lee VM, Trojanowski JQ. 2001. Synucleinopathies: Clinical and pathological implications. Arch Neurol 58: 186-190.
78. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD. 2003. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand 108: 368-373.
79. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, Mathis CA, Elmaleh DR, Shoup T, Fischman AJ, et al. 2008. Imaging amyloid deposition in Lewy body diseases. Neurology 71: 903-910.
80. Grady CL, Springer MV, Hongwanishkul D, McIntosh AR, Winocur G. 2006. Age-related changes in brain activity across the adult lifespan. J Cogn Neurosci 18: 227-241.
81. Green J, McDonald WM, Vitek JL, Evatt M, Freeman A, Haber M, Bakay RA, Triche S, Sirockman B, DeLong MR. 2002. Cognitive impairments in advanced PD without dementia. Neurology 59: 1320-1324.
82. Habeck C, Stern Y. 2010. Multivariate data analysis for neuroimaging data: Overview and application to Alzheimer's disease. Cell Biochem Biophys 58: 53-67.
83. Habeck C, Krakauer JW, Ghez C, Sackeim HA, Eidelberg D, Stern Y, Moeller JR. 2005. A new approach to spatial covariance modeling of functional brain imaging data: Ordinal trend analysis. Neural Comput 17: 1602-1645.
84. Habeck C, Foster NL, Perneczky R, Kurz A, Alexopoulos P, Koeppe RA, DrzezgaA, Stern Y. 2008. Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. Neuroimage 40: 1503-1515.
85. Hallett PJ, Brotchie JM. 2007. Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. Mov Disord 22: 28-40.
86. Helmich RC, Derikx LC, Bakker M, Scheeringa R, Bloem BR, Toni I. 2010. Spatial remapping of cortico-striatal connectivity in Parkinson's disease. Cereb Cortex 20: 1175-1186.
87. 133Xenon before and after levodopa. Acta Neurol Scand 71: 257-266.
88. Herholz K, Bauer B, Wienhard K, Kracht L, Mielke R, Lenz MO, Strotmann T, Heiss WD. 2000. In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: Comparison with blood flow and glucose metabolism. J Neural Transm 107: 1457-1468.
89. Hershey T, Black KJ, Stambuk MK, Carl JL, McGee-Minnich LA, Perlmutter JS. 1998. Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. Proc Natl Acad Sci 95: 12016-12021.
90. Hershey T, Black KJ, Carl JL, McGee-Minnich L, Snyder AZ, Perlmutter JS. 2003. Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease. J Neurol Neurosurg Psychiatry 74: 844-851.
91. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD. 2005. Dementia in Parkinson disease: Functional imaging of cholinergic and dopaminergic pathways. Neurology 65: 1716-1722.
92. Hirano S, Asanuma K, Ma Y, Tang C, Feigin A, Dhawan V, Carbon M, EidelbergD. 2008. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J Neurosci 28: 4201-4209.
93. Hirano S, Dhawan V, Eidelberg D. 2010. PET Imaging in movement disorders. In Encyclopedia of movement disorders (ed. Kompoliti K, Verhagen L), pp. 452-461. Academic Press, New York.
94. Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, Suzuki K, Itoyama Y, Takahashi S, Fukuda H, et al. 2009. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Mov Disord 24: 854-862.
95. Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. 2007a. Metabolic brain networks associated with cognitive function in Parkinson's disease. Neuroimage 34: 714-723.
96. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D. 2007b. Changes in network activity with the progression of Parkinson's disease. Brain 130: 1834-1846.
97. Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. 2008. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 70: 1470-1477.
98. Iadecola C. 1998. Neurogenic control of the cerebral microcirculation: Is dopamine minding the store? Nat Neurosci 1: 263-265.
99. Irie T, Fukushi K, Namba H, Iyo M, Tamagami H, Nagatsuka S, Ikota N. 1996. Brain acetylcholinesterase activity: Validation of a PET tracer in a rat model of Alzheimer's disease. J Nucl Med 37: 649-655.
100. Isaias IU, Benti R, Cilia R, Canesi M, Marotta G, Gerundini P, Pezzoli G, AntoniniA. 2007. [123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset. Neuroreport 18: 1499-1502.
101. Isaias IU, Marotta G, Hirano S, Canesi M, Benti R, Righini A, Tang C, Cilia R, Pezzoli G, Eidelberg D, et al. 2010. Imaging essential tremor. Mov Disord 25: 679-686.
102. Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, Hatano K, Abe Y, Yamada T, Kachi T, et al. 2002. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: A 6-[18F]fluoro-L-dopa PET study. Brain 125: 1358-1365.
103. Jellinger K. 1988. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 51: 540-543.
104. Jellinger KA, Seppi K, Wenning GK, Poewe W. 2002. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 109: 329-339.
105. Johansson A, Savitcheva I, Forsberg A, Engler H, Langstrom B, Nordberg A, Askmark H. 2008. [(11)C]-PIB imaging in patients with Parkinson's disease: Preliminary results. Parkinsonism Relat Disord 14: 345-347.
106. Jokinen P, Bruck A, Aalto S, Forsback S, Parkkola R, Rinne JO. 2009. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy. Parkinsonism Relat Disord 15: 88-93.
107. Kas A, Bottlaender M, Gallezot JD, Vidailhet M, Villafane G, Gregoire MC, Coulon C, Valette H, Dolle F, Ribeiro MJ, et al. 2009. Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease. J Cereb Blood Flow Metab 29: 1601-1608.
108. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, et al. 2004. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306-319.
109. Kobari M, Fukuuchi Y, Shinohara T, Obara K, Nogawa S. 1995. Levodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders. J Neurol Sci 128: 212-218.
110. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA. 1996. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 40: 399-410.
111. Kwak Y, Muller ML, Bohnen NI, Dayalu P, Seidler RD. 2010. Effect of dopaminergic medications on the time course of explicit motor sequence learning in Parkinson's disease. J Neurophysiol 103: 942-949.
112. Lang AE. 2011. A critical appraisal of the premotor symptoms of Parkinson's disease: Potential usefulness in early diagnosis and design of neuroprotective trials. Mov Disord 26: 775-783.
113. Lim SY, Lang AE. 2010. The nonmotor symptoms of Parkinson's disease-An overview. Mov Disord 25 (Suppl 1): S123-S130.
114. Lin TP, Carbon M, Tang C, Mogilner AY, Sterio D, Beric A, Dhawan V, EidelbergD. 2008. Metabolic correlates of subthalamic nucleus activity in Parkinson's disease. Brain 131: 1373-1380.
115. Linazasoro G, Antonini A, Maguire RP, Leenders KL. 2004. Pharmacological and PET studies in patients with Parkinson's disease and a short duration-motor response: Implications in the pathophysiology of motor complications. J Neural Transm 111: 497-509.
116. Linazasoro G, Van Blercom N, Bergaretxe A, Inaki FM, Laborda E, Ruiz OrtegaJA. 2009. Levodopa-induced dyskinesias in Parkinson disease are independent of the extent of striatal dopaminergic denervation: A pharmacological and SPECT study. Clin Neuropharmacol 32: 326-329.
117. Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA. 2010. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: Temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 112: 1465-1476.
118. Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marie RM. 2004. Executive processes in Parkinson's disease: FDG-PET and network analysis. Hum Brain Mapp 22: 236-245.
119. Lustig C, Snyder AZ, Bhakta M, O'Brien KC, McAvoy M, Raichle ME, Morris JC, Buckner RL. 2003. Functional deactivations: Change with age and dementia of the Alzheimer type. Proc Natl Acad Sci 100: 14504-14509.
120. Ma Y, Eidelberg D. 2007. Functional imaging of cerebral blood flow and glucose metabolism in Parkinson's disease and Huntington's disease. Mol Imaging Biol 9: 223-233.
121. Ma Y, Tang C, Spetsieris P, Dhawan V, Eidelberg D. 2007. Abnormal metabolic network activity in Parkinson's disease: Test-retest reproducibility. J Cereb Blood Flow Metab 27: 597-605.
122. Ma Y, Huang C, Dyke JP, Pan H, Alsop D, Feigin A, Eidelberg D. 2010. Parkinson's disease spatial covariance pattern: Noninvasive quantification with perfusion MRI. J Cereb Blood Flow Metab 30: 505-509.
123. Ma Y, Peng S, Spetsieris P, Sossi V, Eidelberg D, Doudet DJ. 2011. Abnormal metabolic brain networks in a non-human primate model of parkinsonism. J Cereb Blood Flow Metab doi: 10. 1038/jcbfm. 2011. 166.
124. Maetzler W, Reimold M, Liepelt I, Solbach C, Leyhe T, Schweitzer K, EschweilerGW, Mittelbronn M, Gaenslen A, Uebele M, et al. 2008. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 39: 1027-1033.
125. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, et al. 2009. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 34: 107-112.
126. Margulies DS, Bottger J, Long X, Lv Y, Kelly C, Schafer A, Goldhahn D, AbbushiA, Milham MP, Lohmann G, et al. 2010. Resting developments: A review of fMRI post-processing methodologies for spontaneous brain activity. MAGMA 23: 289-307.
127. Marie RM, Barre L, Dupuy B, Viader F, Defer G, Baron JC. 1999. Relationships between striatal dopamine denervation and frontal executive tests in Parkinson's disease. Neurosci Lett 260: 77-80.
128. Mattay VS, Tessitore A, Callicott JH, Bertolino A, Goldberg TE, Chase TN, HydeTM, Weinberger DR. 2002. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 51: 156-164.
129. Mattis PJ, Tang CC, Ma Y, Dhawan V, Eidelberg D. 2011. Network correlates of the cognitive response to levodopa in Parkinson disease. Neurology 77: 858-865.
130. Melzer TR, Watts R, MacAskill MR, Pearson JF, Rueger S, Pitcher TL, LivingstonL, Graham C, Keenan R, Shankaranarayanan A, et al. 2011. Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease. Brain 134: 845-855.
131. Mentis MJ, McIntosh AR, Perrine K, Dhawan V, Berlin B, Feigin A, Edwards C, Mattis P, Eidelberg D. 2002. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry 159: 746-754.
132. Meyer PM, Strecker K, Kendziorra K, Becker G, Hesse S, Woelpl D, Hensel A, Patt M, Sorger D, Wegner F, et al. 2009. Reduced α4β2*-nicotinic acetylcholine receptor binding and its relationship to mild cognitive and depressive symptoms in Parkinson disease. Arch Gen Psychiatry 66: 866-877.
133. Moeller JR, Nakamura T, Mentis MJ, Dhawan V, Spetsieres P, Antonini A, Missimer J, Leenders KL, Eidelberg D. 1999. Reproducibility of regional metabolic covariance patterns: Comparison of four populations. J Nucl Med 40: 1264-1269.
134. Montastruc JL, Celsis P, Agniel A, Demonet JF, Doyon B, Puel M, Marc-VergnesJP, Rascol A. 1987. Levodopa-induced regional cerebral blood flow changes in normal volunteers and patients with Parkinson's disease. Lack of correlation with clinical or neuropsychological improvements. Mov Disord 2: 279-289.
135. Morrish PK, Sawle GV, Brooks DJ. 1996. Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease. Brain 119 (Pt 6): 2097-2103.
136. Muller U, Wachter T, Barthel H, Reuter M, von Cramon DY. 2000. Striatal [123I]β-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. J Neural Transm 107: 303-319.
137. Mure H, Hirano S, Tang CC, Isaias IU, Antonini A, Ma Y, Dhawan V, EidelbergD. 2011. Parkinson's disease tremor-related metabolic network: Characterization, progression, and treatment effects. Neuroimage 54: 1244-1253.
138. Nagano-Saito A, Liu J, Doyon J, Dagher A. 2009. Dopamine modulates default mode network deactivation in elderly individuals during the Tower of London task. Neurosci Lett 458: 1-5.
139. Niethammer M, Eidelberg D. 2012. Neuroimaging studies in the evaluation of patients with movement disorders. In Tremor, Parkinson's disease and related movement disorders (ed. LeWitt PA). Cambridge University Press, Cambridge.
140. Niethammer M, Feigin A. 2011. Imaging applications to Parkinson's disease clinical trials. In Imaging in Parkinson's disease (ed. Eidelberg D), pp. 181-190. Oxford University Press, New York.
141. Nurmi E, Ruottinen HM, Bergman J, Haaparanta M, Solin O, Sonninen P, RinneJO. 2001. Rate of progression in Parkinson's disease: A 6-[18F]fluoro-L-dopa PET study. Mov Disord 16: 608-615.
142. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, Aarsland D, McKeith IG. 2004. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61: 919-925.
143. O'Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, McKeith IG, Williams ED. 2008. Nicotinic α4β2 receptor binding in dementia with Lewy bodies using 123I-5IA-85380 SPECT demonstrates a link between occipital changes and visual hallucinations. Neuroimage 40: 1056-1063.
144. Oishi N, Hashikawa K, Yoshida H, Ishizu K, Ueda M, Kawashima H, Saji H, Fukuyama H. 2007. Quantification of nicotinic acetylcholine receptors in Parkinson's disease with (123)I-5IA SPECT. J Neurol Sci 256: 52-60.
145. Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, Piccini P. 2006. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: A PET study. Neurology 67: 1612-1617.
146. Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. 2011. Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal 18F-dopa PET study. Neuroimage 56: 1463-1468.
147. Peng S, Ma Y, Flores J, Doudet DJ, Eidelberg D. 2010. Abnormal topography of cerebral glucose metabolism in parkinsonian macaques. J Nucl Med 51: 1753.
148. Peppard RF, Martin WR, Clark CM, Carr GD, McGeer PL, Calne DB. 1990. Cortical glucose metabolism in Parkinson's and Alzheimer's disease. J Neurosci Res 27: 561-568.
149. Piccini P, Weeks RA, Brooks DJ. 1997. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 42: 720-726.
150. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. 1999. The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 45: 577-582.
151. Pimlott SL, Piggott M, Owens J, Greally E, Court JA, Jaros E, Perry RH, Perry EK, Wyper D. 2004. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: In vitro binding study using 5-[(125)i]-a-85380. Neuropsychopharmacology 29: 108-116.
152. Pirker W. 2003. Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it? Mov Disord 18 (Suppl 7): S43-S51.
153. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW. 2004. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 56: 173-181.
154. Poston KL. 2011. Clinical applications. In Imaging in Parkinson's disease (ed. Eidelberg D), pp. 191-202. Oxford University Press, New York.
155. Pourfar M, Tang C, Lin T, Dhawan V, Kaplitt MG, Eidelberg D. 2009. Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET. J Neurosurg 110: 1278-1282.
156. Priori A, Foffani G, Pesenti A, Tamma F, Bianchi AM, Pellegrini M, Locatelli M, Moxon KA, Villani RM. 2004. Rhythm-specific pharmacological modulation of subthalamic activity in Parkinson's disease. Exp Neurol 189: 369-379.
157. Raichle ME, Snyder AZ. 2007. A default mode of brain function: A brief history of an evolving idea. Neuroimage 37: 1083-1090; discussion 1097-1089.
158. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. 2001. A default mode of brain function. Proc Natl Acad Sci 98: 676-682.
159. Rajput AH, Fenton ME, Birdi S, Macaulay R, George D, Rozdilsky B, Ang LC, Senthilselvan A, Hornykiewicz O. 2002. Clinical-pathological study of levodopa complications. Mov Disord 17: 289-296.
160. Rakshi JS, Uema T, Ito K, Bailey DL, Morrish PK, Ashburner J, Dagher A, JenkinsIH, Friston KJ, Brooks DJ. 1999. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study. Brain 122 (Pt 9): 1637-1650.
161. Rascol O, Sabatini U, Brefel C, Fabre N, Rai S, Senard JM, Celsis P, Viallard G, Montastruc JL, Chollet F. 1998. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain 121 (Pt 3): 527-533.
162. Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, Thalamas C, Bonnet AM, Descombes S, Bejjani B, Fabre N, et al. 2001. Idazoxan, an α-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 16: 708-713.
163. Ribeiro MJ, Vidailhet M, Loc'h C, Dupel C, Nguyen JP, Ponchant M, Dolle F, Peschanski M, Hantraye P, Cesaro P, et al. 2002. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol 59: 580-586.
164. Rinne JO, Portin R, Ruottinen H, Nurmi E, Bergman J, Haaparanta M, Solin O. 2000. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol 57: 470-475.
165. Rioux L, Frohna PA, Joyce JN, Schneider JS. 1997. The effects of chronic levodopa treatment on pre-and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Mov Disord 12: 148-158.
166. Ruberg M, Rieger F, Villageois A, Bonnet AM, Agid Y. 1986. Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease. Brain Res 362: 83-91.
167. Schmaljohann J, Gundisch D, Minnerop M, Bucerius J, Joe A, Reinhardt M, Guhlke S, Biersack HJ, Wullner U. 2006. In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease. Nucl Med Biol 33: 305-309.
168. Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N, Ota T, AsahinaM, Fukushi K, Kuwabara S, et al. 2009. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73: 273-278.
169. Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M, AsahinaM, Hattori T, Tanada S, Irie T. 1999. Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 46: 62-69.
170. Smid LM, Vovko TD, Popovic M, Petric A, Kepe V, Barrio JR, Vidmar G, Bresjanac M. 2006. The 2, 6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. Brain Pathol 16: 124-130.
171. Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P. 2003. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure. Mov Disord 18: 487-495.
172. Snow BJ, Tooyama I, McGeer EG, Yamada T, Calne DB, Takahashi H, Kimura H. 1993. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 34: 324-330.
173. Sommer U, Hummel T, Cormann K, Mueller A, Frasnelli J, Kropp J, ReichmannH. 2004. Detection of presymptomatic Parkinson's disease: Combining smell tests, transcranial sonography, and SPECT. Mov Disord 19: 1196-1202.
174. Sossi V, de La Fuente-Fernandez R, Holden JE, Doudet DJ, McKenzie J, StoesslAJ, Ruth TJ. 2002. Increase in dopamine turnover occurs early in Parkinson's disease: Evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab 22: 232-239.
175. Sossi V, de la Fuente-Fernandez R, Holden JE, Schulzer M, Ruth TJ, Stoessl J. 2004. Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: Their relation to disease-compensatory mechanisms. J Cereb Blood Flow Metab 24: 869-876.
176. Sossi V, de la Fuente-Fernandez R, Schulzer M, Adams J, Stoessl J. 2006. Age-related differences in levodopa dynamics in Parkinson's: Implications for motor complications. Brain 129: 1050-1058.
177. Spetsieris PG, Eidelberg D. 2011. Scaled subprofile modeling of resting state imaging data in Parkinson's disease: Methodological issues. Neuroimage 54: 2899-2914.
178. Spetsieris P, Ma Y, Dhawan V, Moeller JR, Eidelberg D. 2006. Highly automated computer-aided diagnosis of neurological disorders using functional brain imaging. Proc SPIE: Medical Imaging 6144: 61445M.
179. Spetsieris PG, Ma Y, Dhawan V, Eidelberg D. 2009. Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. Neuroimage 45: 1241-1252.
180. Stiasny-Kolster K, Doerr Y, Moller JC, Hoffken H, Behr TM, Oertel WH, Mayer G. 2005. Combination of "idiopathic" REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128: 126-137.
181. Tang CC, Poston KL, Dhawan V, Eidelberg D. 2010a. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease. J Neurosci 30: 1049-1056.
182. Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, Dhawan V, Lesser M, Vonsattel JP, Fahn S, et al. 2010b. Differential diagnosis of parkinsonism: A metabolic imaging study using pattern analysis. Lancet Neurol 9: 149-158.
183. Tang CC, Niethammer M, Gerber NJ, Mattis P, Ma Y, Eidelberg D. 2011. Expression of a cognitive metabolic network in Parkinson's disease correlates with dopaminergic function in caudate nucleus. Neurology 76: A489-A490.
184. Thobois S, Jahanshahi M, Pinto S, Frackowiak R, Limousin-Dowsey P. 2004. PET and SPECT functional imaging studies in Parkinsonian syndromes: From the lesion to its consequences. Neuroimage 23: 1-16.
185. Tinaz S, Schendan HE, Stern CE. 2008. Fronto-striatal deficit in Parkinson's disease during semantic event sequencing. Neurobiol Aging 29: 397-407.
186. Tolosa E, Gaig C, Santamaria J, Compta Y. 2009. Diagnosis and the premotor phase of Parkinson disease. Neurology 72: S12-S20.
187. Troiano AR, de la Fuente-Fernandez R, Sossi V, Schulzer M, Mak E, Ruth TJ, Stoessl AJ. 2009. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 72: 1211-1216.
188. Trost M, Su S, Su P, Yen RF, Tseng HM, Barnes A, Ma Y, Eidelberg D. 2006. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage 31: 301-307.
189. Tuor UI, Edvinsson L, McCulloch J. 1986. Catecholamines and the relationship between cerebral blood flow and glucose use. Am J Physiol 251: H824-H833.
190. Turjanski N, Lees AJ, Brooks DJ. 1997. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 49: 717-723.
191. van Beilen M, Portman AT, Kiers HA, Maguire RP, Kaasinen V, Koning M, PruimJ, Leenders KL. 2008. Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: A clinical and FDOPA-PET study. Parkinsonism Relat Disord 14: 224-228.
192. van de Ven VG, Formisano E, Prvulovic D, Roeder CH, Linden DE. 2004. Functional connectivity as revealed by spatial independent component analysis of fMRI measurements during rest. Hum Brain Mapp 22: 165-178.
193. van Eimeren T, Monchi O, Ballanger B, Strafella AP. 2009. Dysfunction of the default mode network in Parkinson disease: A functional magnetic resonance imaging study. Arch Neurol 66: 877-883.
194. Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. 1994. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 36: 759-764.
195. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. 1997. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 41: 58-64.
196. Westin JE, Lindgren HS, Gardi J, Nyengaard JR, Brundin P, Mohapel P, Cenci MA. 2006. Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3, 4-dihydroxyphenyl-L-alanine-induced dyskinesia. J Neurosci 26: 9448-9461.
197. Whitehouse PJ, Hedreen JC, White CL III., Price DL. 1983. Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 13: 243-248.
198. Whitehouse PJ, Martino AM, Wagster MV, Price DL, Mayeux R, Atack JR, KellarKJ. 1988. Reductions in [3H]nicotinic acetylcholine binding in Alzheimer's disease and Parkinson's disease: An autoradiographic study. Neurology 38: 720-723.
199. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, RascolO, Ribeiro MJ, Remy P, et al. 2003. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 54: 93-101.
200. Wu T, Long X, Zang Y, Wang L, Hallett M, Li K, Chan P. 2009. Regional homogeneity changes in patients with Parkinson's disease. Hum Brain Mapp 30: 1502-1510.
201. Ye L, Velasco A, Fraser G, Beach TG, Sue L, Osredkar T, Libri V, Spillantini MG, Goedert M, Lockhart A. 2008. In vitro high affinity α-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem 105: 1428-1437.
202. Yong SW, Yoon JK, An YS, Lee PH. 2007. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 14: 1357-1362.
203. Zang Y, Jiang T, Lu Y, He Y, Tian L. 2004. Regional homogeneity approach to fMRI data analysis. Neuroimage 22: 394-400.